Acquisition Upside RxTPL was acquired by McKesson Pharma in 2018, signaling stability, access to broader distribution networks, and potential cross-sell opportunities for McKesson’s customers seeking compliant and scalable 3PL solutions.

Scale Potential As a small healthcare 3PL with 2-10 employees and revenue in the low millions, RxTPL presents a high upside for scalable logistics, technology enhancements, and expanded service lines to compete with larger incumbents.

Full Service Hook Clients benefit from end-to-end services including implementation, logistics management, order-to-cash, and EDI, creating cross-sell opportunities into related pharmaceutical services, licensing, and reporting offerings.

Tech Enablement Existing tech stack and real time dashboards indicate openness to analytics-driven operations; this can be leveraged to pitch advanced cloud-based visibility, data integration, and performance insights to potential pharma clients.

Compliance & Reach State licensing management and government pricing/reporting capabilities address regulatory needs, suggesting opportunities to win business with manufacturers and distributors requiring compliant, cost-efficient 3PL partnerships.